Insight Capital Research & Management Inc. Has $2.70 Million Position in PRA Health Sciences, Inc. (PRAH)

Insight Capital Research & Management Inc. lowered its position in PRA Health Sciences, Inc. (NASDAQ:PRAH) by 6.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 35,389 shares of the medical research company’s stock after selling 2,608 shares during the quarter. PRA Health Sciences comprises about 1.5% of Insight Capital Research & Management Inc.’s holdings, making the stock its 17th biggest holding. Insight Capital Research & Management Inc. owned approximately 0.06% of PRA Health Sciences worth $2,696,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Aperio Group LLC purchased a new position in PRA Health Sciences during the second quarter worth about $233,000. Sei Investments Co. boosted its stake in shares of PRA Health Sciences by 4.9% in the second quarter. Sei Investments Co. now owns 14,654 shares of the medical research company’s stock valued at $1,100,000 after purchasing an additional 690 shares during the period. Schwab Charles Investment Management Inc. boosted its stake in shares of PRA Health Sciences by 10.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 234,930 shares of the medical research company’s stock valued at $17,623,000 after purchasing an additional 22,303 shares during the period. First Trust Advisors LP boosted its stake in shares of PRA Health Sciences by 21.1% in the second quarter. First Trust Advisors LP now owns 100,399 shares of the medical research company’s stock valued at $7,531,000 after purchasing an additional 17,519 shares during the period. Finally, Rhumbline Advisers boosted its stake in shares of PRA Health Sciences by 48.5% in the second quarter. Rhumbline Advisers now owns 44,149 shares of the medical research company’s stock valued at $3,312,000 after purchasing an additional 14,413 shares during the period. 98.49% of the stock is owned by hedge funds and other institutional investors.

Shares of PRA Health Sciences, Inc. (PRAH) opened at $83.75 on Tuesday. The firm has a market cap of $5,241.31, a P/E ratio of 30.41, a P/E/G ratio of 1.43 and a beta of 0.40. PRA Health Sciences, Inc. has a 1-year low of $53.47 and a 1-year high of $84.38. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 1.38.

PRA Health Sciences (NASDAQ:PRAH) last issued its earnings results on Wednesday, October 25th. The medical research company reported $0.88 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.85 by $0.03. PRA Health Sciences had a net margin of 5.64% and a return on equity of 21.66%. The firm had revenue of $494.55 million for the quarter, compared to analysts’ expectations of $477.89 million. During the same quarter last year, the company earned $0.64 earnings per share. The firm’s revenue was up 23.7% compared to the same quarter last year. equities analysts forecast that PRA Health Sciences, Inc. will post 3.2 EPS for the current year.

In other PRA Health Sciences news, Director Matthew P. Young sold 5,115 shares of the firm’s stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $79.90, for a total transaction of $408,688.50. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 2.10% of the stock is currently owned by company insiders.

Several research analysts have recently commented on PRAH shares. Zacks Investment Research raised shares of PRA Health Sciences from a “hold” rating to a “buy” rating and set a $83.00 price objective for the company in a research note on Tuesday, August 15th. Credit Suisse Group reissued an “outperform” rating and issued a $90.00 price objective (up previously from $84.00) on shares of PRA Health Sciences in a research note on Monday, October 16th. Raymond James Financial started coverage on shares of PRA Health Sciences in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $89.00 price objective for the company. Mizuho started coverage on shares of PRA Health Sciences in a research note on Thursday, September 21st. They issued a “buy” rating and a $82.00 price objective for the company. Finally, Jefferies Group reissued a “buy” rating and issued a $95.00 price objective on shares of PRA Health Sciences in a research note on Thursday, October 26th. One equities research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $89.50.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://ledgergazette.com/2017/12/12/insight-capital-research-management-inc-has-2-70-million-position-in-pra-health-sciences-inc-prah.html.

About PRA Health Sciences

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply